[go: up one dir, main page]

WO2020008320A8 - Anti-xylan sulfate polyclonal antiserum and use thereof in elisa methods - Google Patents

Anti-xylan sulfate polyclonal antiserum and use thereof in elisa methods Download PDF

Info

Publication number
WO2020008320A8
WO2020008320A8 PCT/IB2019/055557 IB2019055557W WO2020008320A8 WO 2020008320 A8 WO2020008320 A8 WO 2020008320A8 IB 2019055557 W IB2019055557 W IB 2019055557W WO 2020008320 A8 WO2020008320 A8 WO 2020008320A8
Authority
WO
WIPO (PCT)
Prior art keywords
elisa methods
xylan sulfate
polyclonal antiserum
xylan
sulfate
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/IB2019/055557
Other languages
French (fr)
Other versions
WO2020008320A1 (en
Inventor
Flavio Leoni
Giuliana Porro
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chemi SpA
Original Assignee
Chemi SpA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chemi SpA filed Critical Chemi SpA
Priority to EP19742491.4A priority Critical patent/EP3818374A1/en
Priority to US17/252,612 priority patent/US20210253674A1/en
Priority to CA3104604A priority patent/CA3104604A1/en
Publication of WO2020008320A1 publication Critical patent/WO2020008320A1/en
Publication of WO2020008320A8 publication Critical patent/WO2020008320A8/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/06—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies from serum
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/543—Immunoassay; Biospecific binding assay; Materials therefor with an insoluble carrier for immobilising immunochemicals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2400/00—Assays, e.g. immunoassays or enzyme assays, involving carbohydrates
    • G01N2400/10—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • G01N2400/12—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar
    • G01N2400/24—Homoglycans, i.e. polysaccharides having a main chain consisting of one single sugar beta-D-Glucans, i.e. having beta 1,n (n=3,4,6) linkages between saccharide units, e.g. xanthan

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The object of the present invention is an anti-xylan sulfate antiserum having an antibody titre of between 1/10000 and 1/15000, and obtainable using a specific immunization method, and use thereof in one or more ELISA methods for determining xylan sulfate levels in biological fluids.
PCT/IB2019/055557 2018-07-02 2019-07-01 Tianti-xylan sulfate polyclonal antiserum and use thereof in elisa methods Ceased WO2020008320A1 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
EP19742491.4A EP3818374A1 (en) 2018-07-02 2019-07-01 Anti-xylan sulfate polyclonal antiserum and use thereof in elisa methods
US17/252,612 US20210253674A1 (en) 2018-07-02 2019-07-01 Anti-xylan sulfate polyclonal antiserum and use thereof in elisa methods
CA3104604A CA3104604A1 (en) 2018-07-02 2019-07-01 Anti-xylan sulfate polyclonal antiserum and use thereof in elisa methods

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT201800006849 2018-07-02
IT102018000006849 2018-07-02

Publications (2)

Publication Number Publication Date
WO2020008320A1 WO2020008320A1 (en) 2020-01-09
WO2020008320A8 true WO2020008320A8 (en) 2020-03-26

Family

ID=63762797

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/IB2019/055557 Ceased WO2020008320A1 (en) 2018-07-02 2019-07-01 Tianti-xylan sulfate polyclonal antiserum and use thereof in elisa methods

Country Status (4)

Country Link
US (1) US20210253674A1 (en)
EP (1) EP3818374A1 (en)
CA (1) CA3104604A1 (en)
WO (1) WO2020008320A1 (en)

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016170158A1 (en) * 2015-04-24 2016-10-27 Bene Pharmachem Gmbh & Co. Kg Method of detecting and/or quantifying pentosan polysulfate sodium
WO2016191698A1 (en) * 2015-05-27 2016-12-01 Vanguard Therapeutics, Inc. Pentosan polysulfate sodium for the treatment of sickle cell disease

Also Published As

Publication number Publication date
WO2020008320A1 (en) 2020-01-09
CA3104604A1 (en) 2020-01-09
EP3818374A1 (en) 2021-05-12
US20210253674A1 (en) 2021-08-19

Similar Documents

Publication Publication Date Title
CL2020001974A1 (en) Anti-trem2 antibodies and methods of using them. (divisional request 201903093)
MX2021005394A (en) Co-formulations of anti-lag3 antibodies and anti-pd-1 antibodies.
CL2020003391A1 (en) Anti-steap1 antigen binding protein
MY205672A (en) Anti-phf-tau antibodies and uses thereof
WO2017075432A3 (en) Anti-siglec-9 antibodies and methods of use thereof
MX2020013324A (en) Anti-sirp-beta1 antibodies and methods of use thereof.
MY207418A (en) Methods for mitigating drug target interference in an anti-drug antibody (ada) immunoassay
CR20230581A (en) Anti-ccr8 antibodies and uses thereof
EP3705497A4 (en) Anti-human pcsk9 monoclonal antibody and use thereof
MX2021012692A (en) Anti-mertk antibodies and their methods of use.
EP4067385A4 (en) Monoclonal antibody for detection of car-t cells, kit and application
CR20200404A (en) Anti-klk5 antibodies and methods of use
EP4043490A4 (en) HUMANIZED ANTI-VEGF FAB ANTIBODY FRAGMENT AND ITS USE
MX2021010119A (en) Combination therapy involving anti-cd39 antibodies and anti-pd-1 or anti-pd-l1 antibodies.
EP4019541A4 (en) HUMANIZED MONOCLONAL ANTIBODY AGAINST THE NEW CORONAVIRUS 2019 AND ITS USE
BR112022024262A2 (en) METHODS OF TREATMENT OF IGA NEPHROPATHY WITH AN APRIL-BINDING ANTIBODY
IL283881A (en) Anti-il-17a antibody and use thereof
ZA202101668B (en) Humanized anti-vegfr2 single-chain antibody and use thereof
MY199149A (en) Antibody that binds to vegf and il-1beta and methods of use
PH12022551471A1 (en) Antibodies against integrin alpha 11 beta 1
MY208387A (en) Antibodies specifically recognizing pseudomonas pcrv and uses thereof
WO2020008320A8 (en) Anti-xylan sulfate polyclonal antiserum and use thereof in elisa methods
MX2021015336A (en) Modified dosage of subcutaneous tocilizumab for rheumatoid arthritis.
WO2018102594A8 (en) Methods of treating solid tumors with anti-cd200 antibodies
MX2018013523A (en) Dna monoclonal antibodies targeting il-6 and cd126.

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19742491

Country of ref document: EP

Kind code of ref document: A1

ENP Entry into the national phase

Ref document number: 3104604

Country of ref document: CA

NENP Non-entry into the national phase

Ref country code: DE

ENP Entry into the national phase

Ref document number: 2019742491

Country of ref document: EP

Effective date: 20210202